Nu Skin Adds Galvanic Body Device, R2 Supplement To ageLOC Line
Building on its profitable ageLOC portfolio, which has generated $700 million in sales in the short three-year span the products have been on the market, Nu Skin Enterprise, Inc. launches two new products this month. The ageLOC Galvanic Body Spa skin-treatment system (with accompanying body-shaping gel and body-contouring lotion) will bow in the U.S., Europe and South Pacific markets, while the ageLOC R2 supplement system is rolling out in Japan and Korea.
Explore how consumer health is evolving. On the go.
More from Asia
A round-up of the latest global health and wellness moves: Nestlé and Dr Reddy's name JV head; Be-sup hires comms and regulatory director; Ascendis Health appoints interim CFO.
Mentholatum says two line extensions made with 2% salicylic acid and its "Oxy for Every Kind of Ne" campaign reinforce the brand’s “commitment to tackling every type of acne—from face-ne and chin-ne to body-ne.”
Request to recall eye drops should be fulfilled promptly and businesses providing lip balms as promotional products must verify contract manufacturers are compliant, recent FDA warnings states. Additional letters went to Jordanian firm about testing alcohol for methane and to a Chinese firm advised that compliance with China’s quality control standards isn’t sufficient.
Round-up of the latest appointments in the health and wellness markets outside the US: Bayer names joint LATAM/APAC president; Haleon adds directors to board; Bionorica hires global marketing head.
More from Geography
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.